AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22544579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab maintenance every 21 days after initial treatment with bevacizumab 15 mg/kg, pemetrexed 500 mg/m², and carboplatin AUC 6 every 21 days for 6 cycles.
Number of subjects: 43
Study 22544579 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with bevacizumab, pemetrexed, and carboplatin.
Number of subjects: 43
Study 22544579 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related grade 3/4 toxicities during initial treatment.
Number of subjects: 43
Study 19240743 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exposure to GSM signal from a mobile phone for 40 minutes
Number of subjects: 11
Study 19240743 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 11
Study 18089866 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus PCV chemotherapy
Number of subjects: 368
Study 18089866 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 368
Study 15333687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored CPT-11 + S-1
Number of subjects: 0
Study 15333687 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 0
Study 11696471 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy (group W)
Number of subjects: 9
Study 11696471 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy (subject A)
Number of subjects: 9
Study 11696471 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 9
Study 10771920 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory brainstem responses in high risk neonates
Number of subjects: 50
Study 10771920 — intervention group
Group type: COMPARATOR
Intervention: Auditory brainstem responses in normal neonates
Number of subjects: 50
Study 10771920 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months for high risk neonates
Number of subjects: 50
Study 8198691 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT training method
Number of subjects: 2
Study 8198691 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelling training method
Number of subjects: 2
Study 8198691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training methods
Number of subjects: 2
Study 8198691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 2467116 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (mean daily dose 8.8 mg, range 5‐10 mg)
Number of subjects: 125
Study 2467116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (mean daily dose 83.7 mg, range 50‐100 mg)
Number of subjects: 125
Study 2467116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 31851983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional interventions focusing on caloric intake and energy supplementation to prevent protein-energy wasting (PEW)
Number of subjects: 0
Study 31851983 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 0
Study 31851983 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition-inflammation score (KALANTAR Score)
Number of subjects: 0
Study 31851983 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative approaches by physicians and dieticians
Number of subjects: 0
Study 31597591 — intervention group
Group type: EXPERIMENTAL
Intervention: Support package including a website, printed booklet, and cognitive-behavioral therapy-based sessions delivered by a qualified practitioner
Number of subjects: 77
Study 28623947 — intervention group
Group type: EXPERIMENTAL
Intervention: digital automated CBT‐I delivered by a web and/or mobile platform (in addition to treatment as usual (TAU))
Number of subjects: 404
Study 28623947 — intervention group
Group type: COMPARATOR
Intervention: wait‐list control (in addition to TAU)
Number of subjects: 404
Study 25922158 — intervention group
Group type: EXPERIMENTAL
Intervention: Back on Track intervention
Number of subjects: 86
Study 25922158 — intervention group
Group type: COMPARATOR
Intervention: Primary care physiotherapy as usual
Number of subjects: 86
Study 23535184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy
Number of subjects: 95
Study 21277704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Role Induction (IRI)
Number of subjects: 240
Study 21277704 — intervention group
Group type: EXPERIMENTAL
Intervention: IRI+CM
Number of subjects: 240
Study 21277704 — intervention group
Group type: EXPERIMENTAL
Intervention: IRI
Number of subjects: 240
Study 21277704 — intervention group
Group type: COMPARATOR
Intervention: Standard Clinic Treatment (ST)
Number of subjects: 240
Study 19098847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 1000
Study 19098847 — intervention group
Group type: COMPARATOR
Intervention: Regular colonoscopy (RC)
Number of subjects: 1000
Study 16483155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasovasostomy
Number of subjects: 88
Study 16483155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm concentration > 20 x 10(6)/ml
Number of subjects: 88
Study 16483155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm reappearance
Number of subjects: 88
Study 16483155 — intervention group
Group type: COMPARATOR
Intervention: Pregnant group
Number of subjects: 88
Study 15298643 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 12.5 mg
Number of subjects: 120
Study 15298643 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 50 mg
Number of subjects: 120
Study 15298643 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 75 mg
Number of subjects: 120
Study 15298643 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg
Number of subjects: 120
Study 10767506 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller-Ball ablation
Number of subjects: 30
Study 10767506 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel IUD (MIRENA)
Number of subjects: 30
Study 8863967 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 17
Study 8863967 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 17
Study 1385919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with sufentanil (group A)
Number of subjects: 46
Study 1385919 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with morphine (group B)
Number of subjects: 46
Study 6741887 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal preparation procedure
Number of subjects: 40
Study 6741887 — intervention group
Group type: COMPARATOR
Intervention: Usual preparation (Control)
Number of subjects: 40
Study 30009554 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy
Number of subjects: 242
Study 28485483 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation (brief self-affirming exercise)
Number of subjects: 50
Study 28485483 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical questionnaire without self-affirming exercise)
Number of subjects: 50
Study 25664775 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg
Number of subjects: 92
Study 25664775 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 40 mg
Number of subjects: 92
Study 25664775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 24268218 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 3687
Study 24268218 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3687
Study 21135531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological therapy (holistic cognitive rehabilitation program)
Number of subjects: 176
Study 21135531 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 176
Study 19799537 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (postoperative use)
Number of subjects: 2230
Study 19799537 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (premedication)
Number of subjects: 2230
Study 17448371 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 to 8 mg daily (n = 110)
Number of subjects: 224
Study 17448371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB) (n = 114)
Number of subjects: 224
Study 17448371 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 224
Study 17448371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 224
Study 15136193 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Parent Training Program
Number of subjects: 882
Study 15136193 — intervention group
Group type: COMPARATOR
Intervention: Usual Head Start services
Number of subjects: 882
Study 11822997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg at bedtime, titrated to 30 mg if needed)
Number of subjects: 26
Study 11822997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9952093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine with arm abducted at 0 degrees
Number of subjects: 80
Study 9952093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine with arm abducted at 90 degrees
Number of subjects: 80
Study 9952093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine with digital compression
Number of subjects: 80
Study 7723155 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1662
Study 7723155 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical management (daily aspirin and risk factor management)
Number of subjects: 1662
Study 2039284 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 482
Study 2039284 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 482
Study 2039284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sump drainage
Number of subjects: 482
Study 6458577 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% topical thymoxamine hydrochloride
Number of subjects: 25
Study 6458577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6734919 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoxymethasone solution 0.25% with salicylic acid 1% and polyol‐fatty esters in ethanolic solution (Ibaril)
Number of subjects: 40
Study 6734919 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate solution 0.1% (Betnovat)
Number of subjects: 40
Study 28473213 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ice slush cooling
Number of subjects: 20
Study 28473213 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegic arrest without ice slush (Control)
Number of subjects: 20
Study 27179830 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided care
Number of subjects: 151
Study 27179830 — intervention group
Group type: COMPARATOR
Intervention: Standard of care HF management
Number of subjects: 151
Study 25546925 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric diet (group II)
Number of subjects: 201
Study 25546925 — intervention group
Group type: COMPARATOR
Intervention: No special diet (group III)
Number of subjects: 201
Study 21838789 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 60‐5521 (5 mg)
Number of subjects: 38
Study 21838789 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 60‐5521 (25 mg)
Number of subjects: 38
Study 21838789 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 60‐5521 (50 mg)
Number of subjects: 38
Study 21838789 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 60‐5521 (all doses)
Number of subjects: 38
Study 21838789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18354392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (FEN)
Number of subjects: 7
Study 18777700 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal implants with immediate restoration using provisional crowns
Number of subjects: 0
Study 18777700 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 16107978 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (n=30)
Number of subjects: 47
Study 16107978 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (n=17)
Number of subjects: 47
Study 14651137 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II‐DR antigens DRB1*15XX
Number of subjects: 26
Study 14651137 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II‐DR antigens DRB1*11XX
Number of subjects: 26
Study 14651137 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II‐DR antigens DRB1*13XX
Number of subjects: 26
Study 10493456 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ipriflavone daily for 12 months
Number of subjects: 103
Study 10493456 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg vitamin D3 daily for 12 months
Number of subjects: 103
Study 10493456 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 103
Study 8672854 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere (docetaxel) at 100 mg/m2 administered in 1 hour perfusion every 21 days
Number of subjects: 0
Study 8672854 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT 11 (irinotecan) at 100-150 mg/m2/week via weekly infusion
Number of subjects: 0
Study 8672854 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT 11 (irinotecan) at 350 mg/m2 every three weeks
Number of subjects: 0
Study 8672854 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT 11 (irinotecan) at 500 mg/m2 with drug support against diarrhea
Number of subjects: 0
Study 1717782 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg cilazapril
Number of subjects: 42
Study 1717782 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg cilazapril
Number of subjects: 42
Study 1717782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6635104 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 19
Study 6635104 — intervention group
Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide + 5 mg amiloride (control group)
Number of subjects: 19
Study 30817466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment of SBP to less than 120 mmHg (SPRINT)
Number of subjects: 12743
Study 30817466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment of SBP to less than 120 mmHg (THIN)
Number of subjects: 12743
Study 30446875 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping intervention (INT-SWI)
Number of subjects: 93
Study 30446875 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping intervention (INT-CYC)
Number of subjects: 93
Study 30446875 — intervention group
Group type: COMPARATOR
Intervention: Jumping intervention (INT-FOO)
Number of subjects: 93
Study 26865650 — intervention group
Group type: EXPERIMENTAL
Intervention: School Breakfast Program (SBP) participation
Number of subjects: 821
Study 26865650 — intervention group
Group type: EXPERIMENTAL
Intervention: Purchasing from corner stores for breakfast
Number of subjects: 821
Study 26865650 — intervention group
Group type: EXPERIMENTAL
Intervention: Skipping breakfast
Number of subjects: 821
Study 26865650 — intervention group
Group type: COMPARATOR
Intervention: Breakfast behaviors across food security levels
Number of subjects: 821
Study 25095659 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Prograf and Advagraf) included in the immunodepression protocol (Group 1)
Number of subjects: 246
Study 25095659 — intervention group
Group type: COMPARATOR
Intervention: No tacrolimus (Group 2)
Number of subjects: 246
Study 22143874 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiologist-driven fine tuning using NAL-NL1 prescription rule
Number of subjects: 73
Study 22143874 — intervention group
Group type: COMPARATOR
Intervention: Patient-driven fine tuning using Amplifit II system
Number of subjects: 73
Study 19160103 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral brush biopsy (OralCDx)
Number of subjects: 75
Study 19160103 — intervention group
Group type: COMPARATOR
Intervention: Synchronous scalpel biopsy
Number of subjects: 75
Study 17174102 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (DIS) 400mg daily + Cognitive Behaviour Therapy (CBT)
Number of subjects: 12
Study 17174102 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50mg daily + Cognitive Behaviour Therapy (CBT)
Number of subjects: 12
Study 17174102 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 12
Study 16372795 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n=18) used the same toothbrush for 3 months
Number of subjects: 36
Study 16372795 — intervention group
Group type: COMPARATOR
Intervention: Group II (n=18) replaced the toothbrush every month
Number of subjects: 36
Study 11786588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel 100 mg/m2
Number of subjects: 29
Study 11786588 — intervention group
Group type: COMPARATOR
Intervention: 3-hour infusion of paclitaxel 100 mg/m2
Number of subjects: 29
Study 9532549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 23
Study 9532549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7989505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal GIFT using a Jansen-Anderson tubal transfer set
Number of subjects: 87
Study 7989505 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal GIFT
Number of subjects: 87
Study 3289947 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 5 mg b.i.d. in addition to HCTZ 25 mg o.m.
Number of subjects: 81
Study 3289947 — intervention group
Group type: COMPARATOR
Intervention: propranolol 80 mg b.i.d. in addition to HCTZ 25 mg o.m.
Number of subjects: 81
Study 5773113 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline + Alcohol
Number of subjects: 21
Study 5773113 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Alcohol
Number of subjects: 21
Study 5773113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 5773113 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study 31505515 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred Walking Speed (PWS)
Number of subjects: 23
Study 31505515 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 23
Study 27445063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL
Number of subjects: 120
Study 27445063 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic acrylic IOL
Number of subjects: 120
Study 25701337 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1000 mg/d)
Number of subjects: 47
Study 25701337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 23141152 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg/d)
Number of subjects: 83
Study 23141152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21406458 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (TC) methotrexate-based strategy
Number of subjects: 299
Study 21406458 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CT) methotrexate-based strategy
Number of subjects: 299
Study 19716589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm treatment with exogenous platelet-activating factor (PAF)
Number of subjects: 92
Study 19716589 — intervention group
Group type: COMPARATOR
Intervention: No sperm treatment with exogenous platelet-activating factor (PAF)
Number of subjects: 92
Study 17382426 — intervention group
Group type: EXPERIMENTAL
Intervention: True vertebral manipulations (VMG)
Number of subjects: 64
Study 17382426 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulations (sham-VMG)
Number of subjects: 64
Study 15612842 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples alcohol‐focused treatment
Number of subjects: 64
Study 15612842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alcohol‐focused spouse involvement and BCT
Number of subjects: 64
Study 15612842 — intervention group
Group type: COMPARATOR
Intervention: Treatment for problem drinkers only (PDO)
Number of subjects: 64
Study 15612842 — intervention group
Group type: COMPARATOR
Intervention: Spouse behavioral support for drinking reduction
Number of subjects: 64
Study 15612842 — intervention group
Group type: COMPARATOR
Intervention: Relationship satisfaction
Number of subjects: 64
Study 15612842 — intervention group
Group type: COMPARATOR
Intervention: Drinking consequences
Number of subjects: 64
Study 11589867 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily (monotherapy)
Number of subjects: 52
Study 11589867 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily + Unoprostone 0.12% twice daily (combination therapy)
Number of subjects: 52
Study 11589867 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone 0.12% twice daily (monotherapy)
Number of subjects: 52
Study 11589867 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone 0.12% twice daily + Latanoprost 0.005% once daily (combination therapy)
Number of subjects: 52
Study 11589867 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study 9269606 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of azithromycin
Number of subjects: 108
Study 9269606 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of ciprofloxacin
Number of subjects: 108
Study 8324868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg intravenous ondansetron
Number of subjects: 125
Study 8324868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg intravenous ondansetron
Number of subjects: 125
Study 8324868 — intervention group
Group type: COMPARATOR
Intervention: 0.015 mg/kg intravenous ondansetron
Number of subjects: 125
Study 3532655 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation test (EST)
Number of subjects: 100
Study 3532655 — intervention group
Group type: COMPARATOR
Intervention: Non-electrostimulation test (non-EST)
Number of subjects: 100
Study 30885800 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) plus TBI education
Number of subjects: 0